CDEX is not always clear in its press releases. Sometimes they even mislead, exaggerate or obfuscate, whether intentionally or by design.
To illustrate, this year-old PR (my comments in parens in green follow red-highlighted text):
TUCSON, AZ–(Marketwire – Oct 3, 2011) – CDEX Inc. (OTCBB: CEXI), a leading developer of chemical detection products, (there has been no evidence at all that cdex is a "leading developer" of chemical detection products, either based on reputation or contracts/sales. This however is a mantra oft repeated.) using patented (I'll give this one a pass since indeed there apparently are a couple of somewhat useful patents associated with cdex) technologies for use in healthcare, safety and security markets, announced today the company has shipped (this has been done to death - 'shipped' gives no indication whatsoever regarding whether or not the shipment was a purchase or lease by/to the recipient, or a gift.) the first ValiMed™ G4 drug validation system to a prominent US based global medical technology company. (I'll also give this one a pass, because contracts at sensitive stages are often written without identifying the name of the other company.) The company intends using the ValiMed G4 as a lab instrument for a research and development project to determine the shelf life of parenteral admixtures with regards to potency over time. (There has been no followup communication indicating the outcome of that R&D project. Is it still ongoing? Has it ended? What was learned?)
The medical technology company is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. The company serves healthcare institutions, life science researchers, clinical laboratories and pharmaceutical companies worldwide.
“We are honored the ValiMed G4 was chosen to play a critical role in this research project which we believe further validates the breadth of use for our technology. We are excited to ship the first unit of our enhanced ValiMed G4 device to an industry leading medical technology and diagnostic company; this relationship should provide an optimum platform to build our ValiMed G4 market penetration and reputation in the industry. (well ... has it? As already noted, no followup public communication - public as befits a public company - at all.) We expect to deliver additional ValiMed G4 units as the market interest continues to spread,” (same comment ... it's a year later and what evidence, if any, is there of spreading market interest?) stated Jeff Brumfield, chairman and chief executive officer of CDEX.
The ValiMed G4 drug validation system helps (present tense 'helps' from a year ago? yet no org names given to support this claim.) healthcare providers ensure patient safety and control costs by reducing medication errors. The patented detection process identifies drug strengths and volume-by-weight in real-time, validating proper dose, diluents and concentration of high-risk compounded medications and treatment solutions. The VG4 device will help (applause, applause. Correct tense and presumably testable against the compliance requirements and guidelines) healthcare facilities comply with Joint Commission compliance requirements and USP 797 guidelines for compounding sterile preparations (CSPs), and will integrate (I'll let this one pass, too, since no doubt the EMR platforms are easily identifiable and CDEX presumably wouldn't make a flat statement that could be easily refuted.) with electronic medical record (EMR) platforms.
About CDEX
CDEX develops, manufactures and globally (let's see ... what are the global countries and organizations that CDEX products have been distributed to? Have any been returned? Were any paid for or were they gifted? These of course are old questions, and ones most of us know the answers to.) distributes products to the healthcare, safety and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched.
(My summary comment on this year-old PR: It raised hope among old and new investors in the company, but as has been the case with this company historically, one can assume nothing came of any of it or additional PRs to that effect would have been published.)
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Similarly, posters here are often less than clear, whether by accident or by design. For the sake of clarity, I earlier indicated with these exact words that "I am a rank amateur (and dumkoff) when it comes to patents."
I don't think those words could be any clearer, and I very much appreciate the efforts of other patent-savvy posters to educate me on patents in general and CDEX patents in particular.
AI
